

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 2, 2026

Agilent: Bravo NGS

RRID:SCR_019473

Type: Tool

Proper Citation

Agilent: Bravo NGS (RRID:SCR_019473)

Resource Information

URL: <https://www.agilent.com/en/product/next-generation-sequencing/hybridization-based-next-generation-sequencing-ngs/ngs-automation-platforms/bravo-ngs-232819>

Proper Citation: Agilent: Bravo NGS (RRID:SCR_019473)

Description: Workstation is built on Bravo automated liquid handling robot preconfigured for library prep and target enrichment using Next-Generation Sequencing protocols. Workstation modules add microplate handling. Intuitive Agilent VWorks software enables setup of preprogrammed protocols and allows users to create custom protocols., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Synonyms: Agilent Bravo NGS Workstation

Resource Type: instrument resource

Keywords: Agilent, NGS, Instrument Equipment

Funding: NIH U24NS120055;
NIH GM137200

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_019473.pdf

Resource Name: Agilent: Bravo NGS

Resource ID: SCR_019473

Alternate IDs: SCR_019475, Model_Number_Agilent_Bravo_NGS

Record Creation Time: 20220129T080345+0000

Record Last Update: 20260801T190632+0000

Ratings and Alerts

No rating or validation information has been found for Agilent: Bravo NGS.

No alerts have been found for Agilent: Bravo NGS.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Kawai M, et al. (2024) Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. British journal of cancer, 131(7), 1158.

Ganly I, et al. (2023) Characterizing the Immune Microenvironment and Neoantigen Landscape of H??rthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities. Cancer research communications, 3(7), 1409.

Rice WG, et al. (2022) Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. Molecular cancer therapeutics, 21(7), 1125.